Table 1.
Demographic features and clinicopathological of Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma patients.
| Feature | HC (n = 6) |
CP (n = 6) |
RPC (n = 22) |
LAPC (n = 8) |
MPC (n = 4) |
p-Value |
|---|---|---|---|---|---|---|
| HIV status | 0.831 | |||||
| Negative, n (%) | 6 (100.0) | 5 (83.3) | 19 (86.4) | 6 (75.0) | 4 (100.0) | |
| Positive, n (%) | 0 (0.0) | 1 (16.7) | 3 (13.6) | 2 (25.0) | 0 (0.0) | |
| Gender | 0.286 | |||||
| female, n (%) | 3 (50.0) | 0 (0.0) | 8 (36.4) | 2 (25.0) | 2 (50.0) | |
| male, n (%) | 3 (50.0) | 6 (100.0) | 14 (63.6) | 6 (75.0) | 2 (50.0) | |
| Smoking | 0.450 | |||||
| no, n (%) | 6 (100.0) | 1 (16.7) | 12 (54.5) | 4 (50.0) | 2 (50.0) | |
| yes, n (%) | 0 (0.0) | 5 (83.3) | 10 (45.5) | 4 (50.0) | 2 (50.0) | |
| Alcohol | 0.962 | |||||
| no, n (%) | 4 (66.67) | 3 (50.0) | 13 (59.1) | 4 (50.0) | 2 (50.0) | |
| yes, n (%) | 2 (33.33) | 3 (50.0) | 9 (40.9) | 4 (50.0) | 2 (50.0) | |
| Age, median (IQR) | 37 (24–54) | 51 (46–57) | 63 (50–67) | 56 (48–62) | 56 (46–70) | 0.439 |
| Obstructive jaundice | 0.013 | |||||
| no, n (%) | 6 (100.0) | 6 (100.0) | 8 (36.4) | 2 (25.0) | 1 (25.0) | |
| yes, n (%) | 0 (0.0) | 0 (0.0) | 14 (63.6) | 6 (75.0) | 3 (75.0) | |
| Cholangitis | 0.145 | |||||
| no, n (%) | 6 (100.0) | 6 (100.0) | 20 (90.9) | 7 (87.5) | 2 (50.0) | |
| yes, n (%) | 0 (0.0) | 0 (0.0) | 2 (9.1) | 1 (12.5) | 2 (50.0) | |
| T2DM | 0.322 | |||||
| no, n (%) | 6 (100.0) | 3 (50.0) | 16 (72.7) | 7 (87.5) | 4 (100.0) | |
| yes, n (%) | 0 (0.0) | 3 (50.0) | 6 (27.3) | 1 (12.5) | 0 (0.0) | |
| Hypertension | 0.560 | |||||
| no, n (%) | 6 (100.0) | 6 (100.0) | 17 (77.3) | 6 (75.0) | 4 (100.0) | |
| yes, n (%) | 0 (0.0) | 0 (0.0) | 5 (22.7) | 2 (25.0) | 0 (0.0) | |
Healthy Controls (HC) are not included in statistical analysis IQR: interquartile range; T2DM: Type 2 Diabetes Mellitus; CP: chronic pancreatitis; RPC: Resectable Pancreatic Ductal Adenocarcinoma; LAPC: Locally Advanced Pancreatic Ductal Adenocarcinoma; MPC: Metastatic Pancreatic Ductal Adenocarcinoma.